Abolghasem Allahyari

Abolghasem Allahyari

Auto-generated profile, based on publicly available information

Abolghasem Allahyari

Division of Hematology and Oncology, Department of Internal Medicine, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 June 2017 in Phytotherapy Research
Verified
Journal Article
Closed access
PDF file
SESepideh Elyasi
Sepideh Elyasi
FSFarzaneh Sadat Rezazadeh Shojaee
Farzaneh Sadat Rezazadeh Shojaee
AAAbolghasem Allahyari
Abolghasem Allahyari
GKGholamreza Karimi
Gholamreza Karimi

7 August 2023 in Toxicology and Applied Pharmacology
Verified
Journal Article
Closed access
ZRZohreh Rezaei
Zohreh Rezaei
KDKazem Dastjerdi
Kazem Dastjerdi
AAAbolghasem Allahyari
Abolghasem Allahyari
SSSoodabeh ShahidSales
Soodabeh ShahidSales
STSahar Talebian
Sahar Talebian
Saman SargaziSaman Sargazi
Saman Sargazi

23 May 2020 in medRxiv
Verified
Preprint
Open access
PDF file
LGLadan Goshayeshi
Ladan Goshayeshi
MRMina Akbari Rad
Mina Akbari Rad
RBRobert Bergquist
Robert Bergquist
AAAbolghasem Allahyari
Abolghasem Allahyari
BHBenyamin Hoseini
Benyamin Hoseini
Background: Coronavirus Disease 2019 (Covid-19) is expanding worldwide. The characteristics of this infection in patients varies from country to country. To move forward, clinical data on infected patients are needed. Here, we report a comparison between fatalities and recovery of patients with severe Covid-19, based on demographic and clinical characteristics. Methods: Between 5 March and 12 May 2020 in Mashhad, Iran, 1,278 of 4,000 suspected Covid-19 patients were confirmed positive by real-time reverse-transcriptase–polymerase-chain-reaction assay of upper respiratory specimens. We compared the demographic, exposure history and clinical symptoms of 925 survivors and 353 fatal cases with confirmed disease. Results: Mean (SD) age for all confirmed patients was 56.9 (18.7) years, 67.1 (15.9) years in fatal cases and 53.0 (18.3) years in survivors. Multivariable logistic regression analysis showed that the outcome of patients was associated with age (OR = 1.049, P = 0.0001, 95% CI = 1.040-1.057). Despite a high burden of Covid-19 infections in the 30-39 and 40-49 year age groups, most of these (89.6% and 87.2%, respectively) recovered. The median (IQR) duration of hospitalization was 9.0 (6.0-14.0) days. The most prevalent co-morbidities were cardiovascular disorders (21%) and diabetes (16.3%). Dyspnoea (72.7%), cough (68.1%) and fever (63.8%) were the most frequent clinical symptoms. Healthcare workers, of whom two (3%) died, comprised 5.2% of infected-cases. Combination antiviral and antibiotic therapy was used in 43.0% of cases. Conclusions: The characteristics of severe Covid-19 varied substantially between fatal cases and survivors, with diabetes and cardiovascular disorders the most prevalent co-morbidities. In contrast to other studies, there were a higher number of fatalities in younger patients in our settings.

13 March 2021 in Archives of Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
RKRozita Khodashahi
Rozita Khodashahi
HNHamid Reza Naderi
Hamid Reza Naderi
ASAlireza Sedaghat
Alireza Sedaghat
AAAbolghasem Allahyari
Abolghasem Allahyari
SSSoroush Sarjamee
Soroush Sarjamee
MKMandana Khodashahi
Mandana Khodashahi
Background: It seems that the risk of developing complications associated with coronavirus disease 2019 (COVID-19) is higher among individuals with weakened immune systems. Objectives: Therefore, this study was carried out to determine the effectiveness of intravenous immunoglobulin (IVIG) for the treatment of patients not entering the intubation phase compared to those entering the intubation phase. Methods: This descriptive case-control study was performed on 26 patients with COVID-19 referring to Imam Reza hospital in Mashhad, Iran, in March 2020. For subjects with COVID-19 not responding to the standard three-drug protocol (i.e., ribavirin, hydroxychloroquine, and lopinavir/ritonavir), three doses of IVIG (0.4 g/kg/day) were added to the protocol. The patients were divided into two groups of subjects not entering the intubation phase and those entering the intubation phase and compared in terms of different variables. Results: The comparison of laboratory findings showed a significant difference before and after receiving IVIG regarding oxygen saturation (P < 0.005), white blood cell (P = 0.001), hemoglobin level (P = 0.0002), lymphocyte count (P = 0.03), and C-reactive protein (P = 0.001). In general, 53.8% and 46.2% of the patients were discharged and expired, respectively. All the subjects not entering the intubation phase were recovered; nevertheless, only one case entering the intubation phase was recovered, and 92.3% of the patients expired. A significant difference was observed between the patients not entering the intubation phase and those entering the intubation phase in terms of mortality (χ2 = 22.28; P < 0.005). Conclusions: In summary, the obtained results of the current study confirmed the therapeutic effects of IVIG on patients with COVID-19. Moreover, better treatment results, shorter hospital stay, and lower mortality rates were observed among COVID-19 patients who did not enter the intubation phase in comparison with those entering the intubation phase.

18 October 2020 in Immunopathologia Persa
Verified
Journal Article
Open access
PDF file
MSMohsen Seddigh-Shamsi
Mohsen Seddigh-Shamsi
SMShima Nabavi Mahali
Shima Nabavi Mahali
MMMahnaz Mozdourian
Mahnaz Mozdourian
AAAbolghasem Allahyari
Abolghasem Allahyari
NSNeda Saeedian
Neda Saeedian
ZBZahra Rezaei Borojerdi
Zahra Rezaei Borojerdi
Introduction:Human coronavirus disease 2019 (COVID-19) is an emerging respiratory disease that has become pandemic worldwide. The patients have a range of mild to severe symptoms, such as pneumonia, acute respiratory distress syndrome, arrhythmia, shock, and other organs involvement. Clinical and hematological evidence can serve as a prognostic factor to detect severe cases of COVID-19. Objectives: The present study aimed to evaluate hematological parameters related to the severity of the disease in COVID-19 patients in Mashhad, Eastern Iran. Patients and Methods: All the individuals with positive real-time reverse transcription-polymerase chain reaction test results and the patients with clinical symptoms whose computed tomography scan results were matched with the diagnosis of viral pneumonia were included in the study. The hematological examinations and complete blood count of the patients were performed by the healthcare personnel through collecting blood samples at the time of admission and discharge from the hospital. Results: In total, 189 COVID-19 patients were included in the study, 47.6% and 58.73% of whom were over 60 years old and male, respectively. Investigation of the hematological parameters revealed that the number of white blood cells, mean value of corpuscular volume, number of platelets, and lymph count had significantly increased at the time of discharge (P<0.01). On the other hand, red blood cells, hemoglobin, hematocrit, mean corpuscular hemoglobin, mean corpuscular hemoglobin, and red cell distribution width values were significantly higher at the time of admission in comparison to discharge (P<0.01). Furthermore, it was found that male gender had a significant relationship with the development of lymphopenia in the patients (P=0.021). Conclusion: It can be concluded that hematological parameters and inflammatory biomarkers in COVID-19 patients could potentially act as the independent factors and affect the prognosis of the disease.

21 November 2022 in Revista da Associação Médica Brasileira
Verified
Journal Article
Open access
MKMaryam Khodashenas
Maryam Khodashenas
ARArezoo Rajabian
Arezoo Rajabian
AAArmin Attaranzadeh
Armin Attaranzadeh
FLFahimeh LaviArab
Fahimeh LaviArab
NANegin Allahyari
Negin Allahyari
AAAbolghasem Allahyari
Abolghasem Allahyari
This study aimed to assess the patterns of serum cytokines in chronic lymphocytic leukemia patients at baseline and post-chemotherapy and investigate their association with response to treatment and chronic lymphocytic leukemia prognosis. Blood samples were taken from 32 subjects at their first medical visit after being diagnosed with chronic lymphocytic leukemia and 1 year after chemotherapy. Then, levels of cytokines and blood parameters in peripheral blood were measured. Correlation analysis was used to assess the indexes before and after chemotherapy as well as at different disease stages. Most of the patients (45.80%) had stages I and III before initiation of treatment and after treatment, respectively. There were significant differences between levels of interleukin (IL)-6 (p=0.006) and IL-10 (p=0.009) before and after treatment. Notably, the difference in IL-10 levels before and after treatment was significantly higher in the advanced stages compared to that in the non-advanced stages (p=0.007). IL-6 and IL-10 were also higher in the expired patients compared to the survived cases. Cytokines such as IL-6 and IL-10 may be considered predicting factors for chronic lymphocytic leukemia prognosis.